Amlodipine/irbesartan - Sanofi

Drug Profile

Amlodipine/irbesartan - Sanofi

Alternative Names: Aimix Combination Tablets HD; Aimix Combination Tablets LD; Amlodipine besilate/irbesartan; Aprovasc; DSP-8153; Irbesartan/amlodipine; Irbesartan/amlodipine besilate

Latest Information Update: 29 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; Sumitomo Dainippon Pharma
  • Class Antihypertensives; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Mar 2015 No recent reports of development identified - Phase-II for Hypertension in South Korea, Philippines, Taiwan and India (PO)
  • 17 Mar 2015 Launched for Hypertension (Treatment-experienced) in Japan, Argentina and Lebanon (PO) before March 2015
  • 17 Mar 2015 No recent reports of development identified - Phase-III for Hypertension (Treatment-experienced) in Russia, Brazil, Venezuela, Morocco, Tunisia, Egypt and United Arab Emirates (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top